Table 1

 Patients’ demographics, treatment regimens, and duration of B cell depletion

Patient NoSex/age (years)/ethnicityDisease duration (years)Regimen for each cycleDuration since previous cycle (months)Main clinical indication for each cyclePrevious treatmentsDuration B cell depletion (months)
E, European; A, Afro-Caribbean; RTX, rituximab; CYC, cyclophosphamide; Pred, oral prednisolone; MP, methylprednisolone; hA20, humanised anti-CD20 monoclonal antibody; HCQ, hydroxychloroquine; AZA, azathioprine; MMF, mycophenolate; MTX, methotrexate; CyA, ciclosporin A.
1F/45/E162×500 mg RTX 2×750 mg CYC 2×60 mg PredArthritis, pleuritis, shrinking lungSteroids, HCQ, AZA, CYC, MMF, MTX, CyA4
2×1000 mg RTX 2×750 mg CYC 2×60 mg Pred7Arthritis, fever, rash6
2×1000 mg RTX 2×750 mg CYC 2×100 mg MP31Arthritis, pleuritis7
2F/21/A82×500 mg RTX 2×750 mg CYC 2×60 mg PredNephritis (IV), arthritisSteroids, HCQ, AZA, CYC, MMF4
2×1000 mg RTX 2×250 mg MP10Nephritis, arthritis, pleuritisNil
3×hA20 (375 mg/m2) 1×500 mg CYC 3×100 mg MP25Nephritis, haemolytic anaemia, thrombocytopeniaPartial depletion at 2 months
3F/52/A152×1000 mg RTX 2×750 mg CYC 2×60 mg PredNephritis (IV), arthritisSteroids, HCQ, AZA, CYC, MTX, CyA6
2×1000 mg RTX 2×250 mg MP7Arthritis9
1×1000 mg RTX 1×750 mg CYC 1×100 mg MP9Nephritis2
4F/41/A112×1000 mg RTX 2×250 mg MPNephritis (IV)Steroids, HCQ, CYC, AZA, MMF, MTX9
2×1000 mg RTX 2×100 mg MP13ArthritisDepleted at 2 months, then lost to follow up
5F/33/E142×1000 mg RTX 1×750 mg CYC 2×100 mg MPNephritis (IV)Steroids, HCQ, AZA, CYC, MMF3
2×1000 mg RTX 2×750 mg CYC 2×100 mg MP3Arthritis, rash, fever6
6F/33/A182×1000 mg RTX 2×750 mg CYC 2×250 mg MPNephritis (V)Steroids, HCQ, AZA, MMF, CYC4
2×1000 mg RTX 2×750 mg CYC 2×100 mg MP11NephritisDepleted at 2 months
2×1000 mg RTX 2×750 mg CYC 2×250 mg MP12Nephritis (IV)Partial depletion at 3 months
7F/42/A52×1000 mg RTX 2×750 mg CYC 2×100 mg MPArthritisSteroids, HCQ, AZA, CYC, MTX, MMF3
2×1000 mg RTX 2×100 mg MP12ArthritisPartial depletion at 6 months